2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow ARQ 197: new trials by email Literature Review of ARQ 197 trials Research Report on ARQ 197
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib ARQ 197 and Erlotinib, Placebo and Erlotinib - Non-small-cell Lung Cancer | Phase 3 | Terminated | Kyowa Kirin Co., Ltd. | 2011-07-01 | 2016-12-07 | |
| Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Tivantinib, Placebo, Erlotinib - Non Squamous, Non-small-cell Lung Cancer | Phase 3 | Terminated | Daiichi Sankyo | 1048 | 2011-01-11 | 2021-04-06 |
Carcinoma, Non-Small-Cell Lung (2)
Daiichi Sankyo (1) · Kyowa Kirin Co., Ltd. (1)
Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Mexico (1)